| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 0450 |
Emergency room services |
121,568 |
109,187 |
$16.72M |
| 0250 |
|
34,333 |
19,316 |
$3.06M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
45,663 |
42,122 |
$2.56M |
| 70450 |
Computed tomography, head or brain; without contrast material |
11,494 |
11,151 |
$2.49M |
| 99199 |
Unlisted special service, procedure or report |
11,544 |
10,817 |
$2.48M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
6,307 |
6,134 |
$2.06M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
16,770 |
13,712 |
$1.70M |
| 80053 |
Comprehensive metabolic panel |
27,734 |
25,833 |
$1.64M |
| 71045 |
Radiologic examination, chest; single view |
31,409 |
29,851 |
$1.26M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
22,928 |
21,179 |
$1.18M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
5,527 |
5,387 |
$1.14M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
8,421 |
7,925 |
$1.14M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,800 |
4,578 |
$1.12M |
| 0301 |
|
4,721 |
4,117 |
$974K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
65,942 |
59,826 |
$960K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,867 |
6,471 |
$904K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
33,976 |
31,025 |
$897K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
7,373 |
7,037 |
$726K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13,122 |
9,609 |
$720K |
| 71046 |
Radiologic examination, chest; 2 views |
8,515 |
8,135 |
$595K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
3,688 |
3,603 |
$593K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
16,182 |
14,642 |
$578K |
| Z7502 |
|
14,739 |
14,274 |
$553K |
| 84484 |
|
26,753 |
23,049 |
$516K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
11,290 |
10,334 |
$474K |
| J3490 |
Unclassified drugs |
35,894 |
23,042 |
$458K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,650 |
3,465 |
$401K |
| 80076 |
|
18,672 |
17,701 |
$368K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
1,535 |
1,499 |
$366K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
11,940 |
10,990 |
$333K |
| 84703 |
|
20,423 |
18,954 |
$330K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
3,673 |
3,525 |
$323K |
| 83690 |
|
25,871 |
24,116 |
$321K |
| 36415 |
Collection of venous blood by venipuncture |
47,215 |
41,342 |
$318K |
| 81001 |
|
29,190 |
27,437 |
$296K |
| 93971 |
|
2,238 |
2,169 |
$286K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12,034 |
11,281 |
$269K |
| 76830 |
Ultrasound, transvaginal |
2,426 |
2,342 |
$268K |
| 76801 |
|
2,229 |
1,881 |
$255K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
487 |
480 |
$214K |
| 73130 |
|
2,316 |
2,232 |
$205K |
| 73562 |
|
2,514 |
2,400 |
$205K |
| 73030 |
|
2,548 |
2,432 |
$204K |
| 87040 |
|
9,173 |
6,468 |
$193K |
| 72100 |
|
1,922 |
1,877 |
$191K |
| 73610 |
|
2,586 |
2,483 |
$186K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
714 |
698 |
$181K |
| 85730 |
|
17,112 |
16,255 |
$181K |
| 73630 |
|
2,560 |
2,462 |
$169K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,847 |
2,448 |
$167K |
| 0762 |
|
1,077 |
673 |
$163K |
| 83880 |
|
6,546 |
6,200 |
$159K |
| 70486 |
|
865 |
846 |
$149K |
| 85610 |
|
18,979 |
17,877 |
$142K |
| 83605 |
|
9,315 |
8,280 |
$140K |
| 0214 |
|
182 |
178 |
$137K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
9,391 |
8,825 |
$136K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
4,091 |
3,668 |
$130K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
6,112 |
5,216 |
$128K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,427 |
2,177 |
$122K |
| 72131 |
|
584 |
574 |
$120K |
| 73110 |
|
1,552 |
1,503 |
$120K |
| 93970 |
|
611 |
599 |
$117K |
| 81003 |
|
14,802 |
14,074 |
$117K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
806 |
727 |
$115K |
| 87631 |
|
849 |
808 |
$111K |
| 85027 |
|
9,642 |
9,028 |
$106K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
22,034 |
18,912 |
$102K |
| 82962 |
|
5,261 |
3,636 |
$100K |
| 76775 |
|
1,055 |
1,014 |
$92K |
| 0270 |
|
16,567 |
9,808 |
$91K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,172 |
1,945 |
$90K |
| 86885 |
|
3,575 |
3,433 |
$81K |
| 73080 |
|
927 |
900 |
$68K |
| 73590 |
|
1,056 |
1,020 |
$67K |
| 87070 |
|
2,460 |
2,368 |
$60K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,348 |
1,264 |
$60K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
13,623 |
11,829 |
$59K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,074 |
1,048 |
$57K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,178 |
1,025 |
$54K |
| 90715 |
|
2,037 |
1,988 |
$53K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,175 |
2,096 |
$53K |
| 0720 |
|
1,015 |
878 |
$52K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,248 |
2,161 |
$52K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
11,024 |
8,981 |
$51K |
| 87186 |
|
3,353 |
3,082 |
$50K |
| 84702 |
|
2,445 |
2,064 |
$50K |
| 70496 |
|
176 |
172 |
$47K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
275 |
271 |
$46K |
| 73564 |
|
494 |
458 |
$46K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
10,808 |
10,034 |
$46K |
| 0272 |
|
711 |
686 |
$46K |
| 0360 |
|
42 |
39 |
$44K |
| 73140 |
|
697 |
680 |
$43K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,614 |
1,220 |
$41K |
| 76870 |
|
283 |
272 |
$40K |
| 73502 |
|
750 |
719 |
$38K |
| 0258 |
|
1,689 |
1,432 |
$37K |
| 83735 |
|
4,738 |
4,258 |
$37K |
| 72040 |
|
437 |
423 |
$36K |
| 74018 |
|
564 |
546 |
$36K |
| 96376 |
|
2,827 |
2,503 |
$34K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
335 |
331 |
$33K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
349 |
339 |
$32K |
| 0710 |
|
644 |
598 |
$30K |
| 86900 |
|
4,304 |
4,074 |
$29K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
5,451 |
5,144 |
$28K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,009 |
3,765 |
$28K |
| 71250 |
|
230 |
225 |
$28K |
| 86901 |
|
4,304 |
4,079 |
$28K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,894 |
1,843 |
$27K |
| Z7610 |
|
5,001 |
3,214 |
$27K |
| 85379 |
|
2,026 |
1,974 |
$26K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
156 |
151 |
$26K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
863 |
805 |
$25K |
| 73090 |
|
580 |
560 |
$25K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
508 |
478 |
$25K |
| 70498 |
|
172 |
169 |
$24K |
| J1815 |
Injection, insulin, per 5 units |
751 |
549 |
$24K |
| 12001 |
|
292 |
282 |
$24K |
| 85007 |
|
3,369 |
3,160 |
$23K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,331 |
2,009 |
$19K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,114 |
2,058 |
$18K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
322 |
300 |
$18K |
| 72170 |
|
738 |
721 |
$17K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
179 |
176 |
$16K |
| 87430 |
|
1,699 |
1,650 |
$15K |
| Z9725 |
|
348 |
345 |
$15K |
| 12011 |
|
110 |
108 |
$14K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
378 |
341 |
$14K |
| A9270 |
Non-covered item or service |
8,498 |
3,000 |
$14K |
| J2060 |
Injection, lorazepam, 2 mg |
3,797 |
3,112 |
$13K |
| 71101 |
|
93 |
93 |
$12K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
2,836 |
1,855 |
$12K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
3,270 |
3,020 |
$12K |
| 0160 |
|
218 |
109 |
$12K |
| 87428 |
|
122 |
121 |
$11K |
| 0949 |
|
99 |
86 |
$11K |
| 10060 |
|
133 |
125 |
$10K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
332 |
322 |
$10K |
| 93458 |
|
40 |
40 |
$10K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
3,047 |
2,772 |
$9K |
| G0378 |
Hospital observation service, per hour |
78 |
73 |
$9K |
| 82150 |
|
1,195 |
1,112 |
$9K |
| 87077 |
|
890 |
827 |
$9K |
| 87147 |
|
946 |
876 |
$9K |
| 87506 |
|
28 |
28 |
$8K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
2,412 |
2,275 |
$8K |
| 84145 |
|
516 |
489 |
$7K |
| 12002 |
|
107 |
101 |
$7K |
| 87088 |
|
930 |
869 |
$6K |
| 29125 |
|
108 |
102 |
$6K |
| 80061 |
Lipid panel |
817 |
795 |
$6K |
| A4649 |
Surgical supply; miscellaneous |
1,843 |
1,135 |
$6K |
| 82550 |
|
901 |
862 |
$6K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
932 |
886 |
$6K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
816 |
262 |
$6K |
| 86140 |
|
1,371 |
1,325 |
$5K |
| 87210 |
|
360 |
345 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
692 |
652 |
$5K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,975 |
1,799 |
$4K |
| 72128 |
|
14 |
13 |
$4K |
| 73552 |
|
68 |
66 |
$4K |
| 73060 |
|
97 |
96 |
$3K |
| 85652 |
|
542 |
519 |
$3K |
| 85018 |
|
1,339 |
1,274 |
$3K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
21 |
14 |
$3K |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,189 |
534 |
$3K |
| A9150 |
Non-prescription drugs |
4,396 |
2,593 |
$3K |
| 82805 |
|
97 |
95 |
$2K |
| 99152 |
|
197 |
186 |
$2K |
| 84100 |
|
654 |
621 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
495 |
483 |
$2K |
| J7050 |
Infusion, normal saline solution, 250 cc |
777 |
659 |
$2K |
| 97162 |
|
118 |
117 |
$2K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
111 |
106 |
$2K |
| 87420 |
|
212 |
197 |
$2K |
| 84439 |
|
341 |
333 |
$2K |
| J2704 |
Injection, propofol, 10 mg |
90 |
80 |
$2K |
| 82010 |
|
182 |
165 |
$2K |
| 59025 |
Fetal non-stress test |
23 |
12 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
243 |
117 |
$2K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
28 |
26 |
$2K |
| 72070 |
|
14 |
13 |
$1K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
26 |
26 |
$1K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
574 |
536 |
$1K |
| S0164 |
Injection, pantoprazole sodium, 40 mg |
197 |
173 |
$1K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
258 |
228 |
$1K |
| 29515 |
|
26 |
25 |
$1K |
| 76770 |
|
43 |
41 |
$1K |
| J1630 |
Injection, haloperidol, up to 5 mg |
221 |
198 |
$998.54 |
| 76641 |
|
13 |
12 |
$939.80 |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
76 |
49 |
$862.57 |
| 82375 |
|
97 |
95 |
$856.29 |
| 96367 |
|
23 |
15 |
$838.18 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
179 |
145 |
$781.41 |
| 0370 |
|
173 |
161 |
$685.77 |
| 71020 |
|
37 |
15 |
$674.19 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
116 |
115 |
$656.63 |
| 82248 |
|
71 |
69 |
$620.38 |
| Z7500 |
|
17 |
12 |
$579.70 |
| 83050 |
|
97 |
95 |
$551.29 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
133 |
123 |
$548.32 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
47 |
39 |
$478.24 |
| 82607 |
|
88 |
87 |
$396.75 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
16 |
16 |
$364.67 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
22 |
19 |
$324.39 |
| 99153 |
Mod sedat endo service >5yrs |
55 |
55 |
$319.61 |
| L3807 |
Wrist hand finger orthosis, without joint(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
12 |
12 |
$309.41 |
| S0028 |
Injection, famotidine, 20 mg |
939 |
896 |
$276.32 |
| 0760 |
|
20 |
20 |
$212.44 |
| 82140 |
|
13 |
13 |
$156.12 |
| 82728 |
|
54 |
54 |
$138.61 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
21 |
12 |
$136.68 |
| 0278 |
|
27 |
27 |
$127.51 |
| 86780 |
|
14 |
13 |
$126.92 |
| J1940 |
Injection, furosemide, up to 20 mg |
35 |
25 |
$126.02 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
12 |
12 |
$120.40 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
16 |
14 |
$105.55 |
| 84550 |
|
69 |
67 |
$93.40 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
30 |
28 |
$61.89 |
| 0324 |
|
560 |
544 |
$60.54 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
14 |
13 |
$57.51 |
| 86308 |
|
29 |
29 |
$54.48 |
| 0300 |
|
648 |
612 |
$51.59 |
| J1953 |
Injection, levetiracetam, 10 mg |
14 |
14 |
$46.77 |
| 83540 |
|
58 |
58 |
$45.53 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
71 |
65 |
$43.09 |
| 0305 |
|
712 |
678 |
$28.35 |
| 83550 |
|
26 |
26 |
$15.34 |
| 0306 |
|
487 |
468 |
$13.60 |
| 82040 |
|
13 |
13 |
$9.70 |
| 87081 |
|
14 |
14 |
$4.54 |
| 99072 |
|
95 |
46 |
$4.00 |
| A4218 |
Sterile saline or water, metered dose dispenser, 10 ml |
28 |
25 |
$3.36 |
| 0307 |
|
275 |
264 |
$0.00 |
| S9445 |
Patient education, not otherwise classified, non-physician provider, individual, per session |
1,930 |
1,042 |
$0.00 |
| 0310 |
|
142 |
139 |
$0.00 |
| 0420 |
|
127 |
114 |
$0.00 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
14 |
14 |
$0.00 |
| 0352 |
|
99 |
98 |
$0.00 |
| J2785 |
Injection, regadenoson, 0.1 mg |
13 |
13 |
$0.00 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
15 |
15 |
$0.00 |
| Q4051 |
Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) |
18 |
13 |
$0.00 |
| 27502 |
|
15 |
15 |
$0.00 |
| 83615 |
|
14 |
14 |
$0.00 |
| 0351 |
|
12 |
12 |
$0.00 |
| 0730 |
|
240 |
231 |
$0.00 |
| 0402 |
|
69 |
68 |
$0.00 |
| 0510 |
|
15 |
13 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
29 |
26 |
$0.00 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
14 |
14 |
$0.00 |
| 0489 |
|
13 |
13 |
$0.00 |
| 0302 |
|
13 |
13 |
$0.00 |
| 93017 |
|
14 |
14 |
$0.00 |